Jefferies initiated coverage of Veradermics (MANE) with a Buy rating and $75 price target The firm thinks the company’s Phase 3 study has a high likelihood of success. The company’s VDPHL01 extended release enables sustained plasma concentrations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MANE:
- Veradermics initiated with an Overweight at Cantor Fitzgerald
- Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO
- Veradermics completes enrollment in Phase 3 trial of VDPHL01
- Veradermics Completes IPO and Adopts New Governance Structure
- Veradermics opens at $34, IPO priced at $17 per share